Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Gemmy Cheung Chui Ming, EURETINA 2019 – Clinical Characteristics of AMD

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 17th 2019

Gemmy Cheung Chui Ming (Singapore National Eye Centre) discusses the unmet needs in the field of AMD and the recent research into the differences in clinical characteristics of AMD in white and Asian patients.

Questions:
1. What are the major unmet needs in the field of AMD?
2. What are the major differences in the clinical characteristics of AMD in white and Asian patients?
3. What is the relationship between choroidal thickness and AMD manifestations?
4. What are the implications of these findings in terms of treatment approaches?

Support: No funding was received in the production of this video.
Disclosures: Gemmy Cheung Chui Ming declares – speaker, consultant and research grants from: Bayer, Novartis, Topcom, Roche, Boehringer Ingelheim and Amgen.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup